ZNF587B

Across TCGA pan-cancer cohorts, ZNF587B Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ZNF587B data layer compared with 24 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher ZNF587B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZNF587B expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

STAD, ESCA, and LGG are the cancer types where ZNF587B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.216	0.689	<.001	30	view →
ESCA	OS	Median	II,III,IV	0.117	0.687	<.001	18	view →
LGG	DFS	Median	All	0.083	0.833	<.001	12	view →
SKCM	OS	Median	III,IV	0.233	0.705	.034	3	view →
BLCA	DFS	Median	III,IV	1.000	0.269	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ZNF587B–STAD (OS)

Open the STAD breakdown →